SRT-1460 is a drug in development by Sirtris Pharmaceuticals intended as a small-molecule activator of the sirtuin subtype SIRT1.

It has similar activity in animal studies to the known SIRT1 activator resveratrol, but is closer in potency to SRT-1720.

In animal studies it was found to improve insulin sensitivity and lower plasma glucose levels in fat, muscle and liver tissue, and increased mitochondrial and metabolic function.

[1] However, the claim that SRT1460 is a SIRT1 activator has been questioned[2] and further defended.

[3] This pharmacology-related article is a stub.